REVA Medical

REVA Medical is a pioneer in bioresorbable polymer technology, having developed 19 polymer families over two decades. Its proprietary Tyrocore polymer platform underpins its commercial and pipeline products, including the CE-marked Fantom Encore coronary scaffold and the MOTIV BTK scaffold, which has FDA Breakthrough Designation. The company's strategy targets the large cardiovascular device market by offering temporary scaffolds that resorb, aiming to improve long-term patient outcomes compared to permanent metal implants. REVA operates as a commercial-stage entity in select European markets while advancing clinical programs for US market entry.

Proprietary tyrosine-derived polycarbonate polymer platform (Tyrocore) for creating radiopaque, bioresorbable medical implants.

In coronaries, REVA competes against dominant permanent metal drug-eluting stents (e.g., from Abbott, Medtronic, Boston Scientific) and other bioresorbable scaffolds. In BTK PAD, competitors include drug-coated balloons, atherectomy devices, and other scaffolds. TyroSphere would compete against established permanent and non-radiopaque embolic beads.